CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Identification of Microorganisms Using Nucleic Acid Probes

Governs coverage and prior authorization for proprietary laboratory analyses using nucleic acid probe and amplification techniques for Medicare Advantage and commercial products of BCBSRI.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIdentification of Microorganisms Using Nucleic Acid Probes

Policy CodePolicy N/A

Change TypeRoutine review — no material clinical or coverage changes

Effective DateJan 1, 2025

Next Review DateAug 20, 2025

Key ActionObtain prior authorization for listed proprietary panels (ePlex BCID 0140U/0141U/0142U) and ensure only the ordering physician requests authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4Proprietary panels listed

~30Individual organisms listed

3Panel types not covered

4PLA CPT codes listed as covered when criteria met

~60References cited

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Medically necessary uses

Covered when medical criteria are met for Medicare Advantage Plans and Commercial Products.

PLA panels allowed: Specific Proprietary Laboratory Analyses (PLA) tests (MicroGenDX qPCR & NGS For Infection — CPT 0112U; ePlex BCID Fungal Pathogens Panel — CPT 0140U; ePlex BCID Gram-Positive Panel — CPT 0141U; ePlex BCID Gram-Negative Panel — CPT 0142U) may be considered medically necessary when the medical criteria below are met.

See test-specific listing and prior authorization requirements.

Medically necessary without quantification: Use of nucleic acid testing using a direct or amplified probe technique (without quantification of viral load) may be considered medically necessary for the listed microorganisms when clinical presentation warrants testing.

Organism list: Bordetella pertussis; Bartonella henselae/r quintana; Candida species; Chlamydia pneumoniae; Chlamydia trachomatis; Clostridium difficile; Enterococcus (including VRE vanA, vanB); Enterovirus; Herpes simplex virus; Human papillomavirus; Influenza virus; Legionella pneumophila; Mycobacterium species (including M. tuberculosis, M. avium-intracellulare); Mycoplasma pneumoniae; Mycoplasma genitalium; Neisseria gonorrhoeae; Rubeola (measles); SARS-CoV-2; Staphylococcus aureus (including MRSA); Streptococcus group A; Streptococcus group B; Trichomonas vaginalis; Zika virus (see source).

Medically necessary with or without quantification: Use of nucleic acid direct or amplified probe techniques (with or without quantification of viral load) may be considered medically necessary for specific viral agents where quantification may be relevant (Hepatitis B virus, Hepatitis C virus, Cytomegalovirus, HIV-1, HIV-2, Human herpesvirus 6).

Quantitative testing applicability listed in policy.

Respiratory panel and additional covered tests: Use of multiplex respiratory virus panels and MicroGenDX qPCR & NGS For Infection (CPT 0112U) may be considered medically necessary when clinical criteria above are met.

Respiratory virus panel and MicroGenDX listed in policy as potential medical necessity when criteria satisfied.

Not medically necessary / Not covered

Not covered / Not medically necessary.

Panels not covered: Nucleic acid–based central nervous system (CNS) pathogen panels and gastrointestinal pathogen panels are not covered / not medically necessary for Medicare Advantage Plans and Commercial Products because the evidence is insufficient to demonstrate an improvement in net health outcome.

Policy cites concerns about sensitivity characterization, false-positives, and lack of defined patient subsets who benefit (see source).

Specific organisms not covered: Direct or amplified probe testing for certain organisms (examples listed in policy: Gardnerella vaginalis; Hepatitis G) is not covered / not medically necessary due to insufficient evidence of net health outcome improvement.

Listed as not covered in policy.

Panel elements and expanded panels: Expanded panel elements or panels that include organisms or targets not supported by evidence in the policy may be excluded as not medically necessary.

See policy statement for details.

The policy explicitly states that nucleic acid-based central nervous system (CNS) pathogen panels and gastrointestinal (GI) pathogen panels are not covered / not medically necessary for Medicare Advantage Plans and Commercial Products because the evidence is insufficient to demonstrate an improvement in net health outcome. This exclusion applies to multiplex panels that simultaneously test for multiple CNS or GI pathogens rather than to individual organism testing when clinical criteria are met.

The policy references regulatory and guideline actions relevant to multiplex GI panels, including the CMS Local Coverage Determination for foodborne gastrointestinal panels (LCD L37709 — noted as retired) and FDA evaluations of GI panel devices. These references and cited studies inform the policy’s determination that evidence is insufficient to support routine coverage of broad GI multiplex panels.

In addition to whole CNS and GI panels, the policy excludes certain panel elements and specific organisms when evidence is insufficient. The policy lists examples (e.g., Gardnerella vaginalis, Hepatitis G) and notes that expanded or non‑standard panel elements that lack demonstrated clinical benefit are considered not covered / not medically necessary.

Covered Indications

Identification of specific infectious agents listed

Identification of specific infectious agents listed in the policy when clinical presentation warrants nucleic acid probe testing and medical criteria are met.

Direct or amplified probe testing — organism list: Direct or amplified nucleic acid testing (without quantification) may be considered medically necessary for the following organisms when clinical indications support testing: Bordetella pertussis; Bartonella henselae/r quintana; Candida species; Chlamydia pneumoniae; Chlamydia trachomatis; Clostridium difficile; Enterococcus (including vancomycin-resistant enterococcus vanA, vanB); Enterovirus; Herpes simplex virus; Human papillomavirus; Influenza virus; Legionella pneumophila; Mycobacterium species (including M. tuberculosis and M. avium-intracellulare); Mycoplasma pneumoniae; Mycoplasma genitalium; Neisseria gonorrhoeae; Rubeola (measles); SARS-CoV-2; Staphylococcus aureus (including MRSA); Streptococcus group A; Streptococcus group B; Trichomonas vaginalis; Zika virus.

Full organism list appears in policy chunk 3.

Quantitative testing indicated: Direct or amplified probe techniques with quantification (viral load) may be medically necessary for agents where viral load influences management: Hepatitis B virus, Hepatitis C virus, Cytomegalovirus, HIV-1, HIV-2, Human herpesvirus 6.

Quantitative methods noted in policy chunk 3.

Not Covered Details

Not covered summary: Central nervous system pathogen panels; Gastrointestinal pathogen panels; and certain panel elements or organisms (for example, Gardnerella vaginalis and Hepatitis G) are explicitly listed as not covered / not medically necessary for Medicare Advantage and Commercial Products.

Rationale for not covered: The policy cites concerns about test performance and clinical utility — including reports of false-positive results and contamination in nucleic acid amplification assays and limitations in sensitivity characterization. Regulatory evaluations and reviews of multiplex GI panels (FDA decision summaries and CMS LCD actions) and the cited clinical studies were considered in concluding that evidence is insufficient to show improved net health outcomes for routine use of these panels.

Coding

Covered CPT Codes (when medical criteria met)CPTCovered

0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and resistance element detection, DNA (20 gram-positive bacterial targets; 4 resistance genes, 1 pan gram-negative bacterial target; 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target; 1 pan Candida target), amplified technique; each target reported as detected or not detected
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene

Provider Actions & Billing

Prior Authorization

Prior Authorization Required

Prior authorization is required for the following Proprietary Laboratory Analyses (PLA) tests for Medicare Advantage Plans and Commercial Products: ePlex BCID Fungal Pathogens Panel (GenMark Diagnostics, Inc.) CPT code 0140U; ePlex BCID Gram-Positive Panel (GenMark Diagnostics, Inc.) CPT code 0141U; ePlex BCID Gram-Negative Panel (GenMark Diagnostics, Inc.) CPT code 0142U; MicroGenDX & NGS For Infection (MicroGenDX) CPT code 0112U.

Covered PLA panels requiring prior authorization: 0140U, 0141U, 0142U, 0112U

Note

Prior Authorization / Benefit Verification

Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement and may vary by product. For member-specific benefits and eligibility verification, contact the BCBSRI provider call center before ordering services.

Contact provider call center for member-specific verification and benefit details

Ordering Requirements

Step Therapy

Ordering physician must obtain authorizations; labs/third parties restricted

Only the ordering physician may obtain authorization and participate in authorization or appeal processes; laboratories and third parties are not permitted to obtain authorizations on the ordering physician's behalf.

Ordering physicians must manage authorization submissions and appeals directly.

Note

Verify benefits and follow participation agreements before ordering

Providers should verify member benefits and eligibility and adhere to payer/provider participation agreements before ordering tests; member subscriber or employer agreements govern benefits.

Contact the provider call center for member-specific benefit information.

Frequency Limits

Frequency limits (policy defaults)

Default frequency ruleNo specific frequency limits are specified in the policy; frequency is determined by medical necessity and the member's benefit agreement.

Effective date for frequency applicationPolicy effective 01/01/2025; apply frequency determinations from this date forward.

Review cyclePolicy last reviewed 08/20/2025; frequency rules subject to review at next policy update.

Frequency limits (member-specific notes)

Member-specific benefits govern frequencyBenefit coverage and any member-specific frequency limits are determined by the member's subscriber agreement or employer agreement and may supersede this policy.

Benefit verification recommendedProviders should contact the provider call center for member-specific benefits and eligibility before ordering tests that may have frequency constraints.

Definitions and Background

Background: Nucleic acid probe and amplification techniques detect organism‑specific DNA or RNA sequences and include direct probe methods, amplified probe methods (such as PCR and transcription‑mediated amplification), and probe methods that provide quantification (e.g., real‑time PCR for viral load). These methods can increase speed and sensitivity compared with culture and, when applicable, provide quantitative results useful for monitoring certain viral infections.

Direct probe technique (detection without amplification)

DefinitionDirect probe technique: detection methods in which nucleic acids are detected without an initial amplification step; generally lower sensitivity than amplified probes.

Clinical implicationDirect assays generally have lower sensitivity than amplified probes; indications for direct and amplified probes without quantification are considered together in this policy.

Typical useUsed to detect organism-specific DNA or RNA when amplification is not required or available.

Amplified probe technique (uses amplification like PCR/TMA without quantification)

References and Guideline Context

Reference and background notes: The policy draws on multiple regulatory and guideline sources and published studies including FDA device decision summaries and evaluations of class designation for GI panels, CMS LCD documentation (noting LCD L37709 retired), CDC burden summaries, and clinical literature assessing multiplex NAAT panels. These sources inform the policy’s assessment of analytical performance, potential for contamination and false positives, and the limited evidence of net clinical benefit for unrestricted panel use.

Revision History

2025-01-01effective_date

Policy effective date established.

2025-08-20last_reviewLatest

Policy last reviewed; review date recorded.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIdentification of Microorganisms Using Nucleic Acid Probes

Policy CodePolicy N/A

Change TypeRoutine review — no material clinical or coverage changes

Effective DateJan 1, 2025

Next Review DateAug 20, 2025

Key ActionObtain prior authorization for listed proprietary panels (ePlex BCID 0140U/0141U/0142U) and ensure only the ordering physician requests authorization.

SourceLink

On This Page

Covered PLA tests: When the above medical criteria are met, the following PLA CPT codes are covered: 0112U (MicroGenDX qPCR & NGS For Infection) and 0140U/0141U/0142U (ePlex BCID panels) per the policy’s coding section.

See coding and policy statement for test-specific CPT descriptions.

Detection of CNS, GI, respiratory, and STI pathogens

Detection of CNS, gastrointestinal, respiratory, and sexually transmitted infection pathogens — clinical contexts cited in studies and guidelines.

CNS pathogens (meningitis/encephalitis): Nucleic acid–based testing for CNS pathogens is discussed in systematic reviews and prospective studies; while multiplex panels can be specific for included organisms, sensitivity varies by pathogen and false-positive rates have been reported — therefore routine use of CNS multiplex panels is not supported as medically necessary by this policy.

References include multicenter evaluations and systematic reviews (see chunks 18 and 13).

Gastrointestinal pathogens: Multiplex gastrointestinal pathogen panels detect bacterial, viral, and parasitic etiologies with higher sensitivity than standard methods in many studies, but the policy concludes evidence is insufficient to define the subset of patients who benefit; routine panel testing is not covered as medically necessary.

Systematic reviews and randomized trials cited (see chunks 21 and 13).

Respiratory pathogens: Multiplex respiratory virus panels reduce time to result and can improve clinical care in some settings; respiratory panels are listed in the policy as tests that may be considered when clinical criteria are met.

Systematic reviews/meta-analyses of respiratory panel utility are cited (see chunk 21 and references).

Sexually transmitted infections (STIs): Nucleic acid testing for STIs (e.g., Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis) is supported by guideline recommendations and cited literature; these agents are included in the policy’s covered organism list when clinical indications warrant testing.

CDC STI treatment and laboratory detection recommendations referenced (see chunk 24).

Documentation Required

Ordering Physician Responsible for Authorization

Only the ordering physician may initiate and be involved in the authorization, appeals, and related administrative processes. Laboratories, laboratory representatives, or any third parties are not permitted to obtain authorization or participate in the authorization process on behalf of the ordering physician.

Authorization must be obtained by the ordering physician only
Third-party or laboratory-initiated authorizations are prohibited

Denial Risk

Prohibition on Third-Party Authorization

In no circumstance shall a laboratory or a representative of a laboratory or any third party obtain authorization or facilitate any portion of the authorization or appeals process on behalf of the ordering physician. If a laboratory or third party is found to have supported any portion of the authorization process, BCBSRI will deem it a violation of policy and may take severe actions up to termination from the BCBSRI provider network.

Prohibition on third-party authorization — violation may result in termination from the network

Billing Rule

Unauthorized Lab Services Denied / Billing Risk

If a participating laboratory provides laboratory services that have not been authorized, those services will be denied and the financial liability will be assigned to the participating laboratory. Providers should verify authorization before rendering services to avoid denials and billing risk to the laboratory or provider.

Unauthorized laboratory services will be denied and billed to the participating laboratory
Services determined not medically necessary or non-covered may result in denial and member/provider billing risk

Billing implicationsServices determined to be not medically necessary or not covered may be denied and cannot be billed to the member unless prior agreement obtained.

DefinitionAmplified probe technique: detection methods in which target, probe, or signal amplification (e.g., PCR, transcription-mediated amplification) is used to improve assay sensitivity without quantification.

ExamplesIncludes PCR (including nested or multiplex PCR), transcription-mediated amplification, nucleic acid sequence-based amplification, strand displacement amplification, and ligase chain reaction.

Performance noteMost commercially available probes are amplified; amplified methods generally provide greater sensitivity than direct probes.

Probe with quantification (quantitative/real-time PCR)

DefinitionProbe with quantification: techniques (eg, quantitative PCR or real-time PCR) that generate absolute or relative amounts of a known nucleic acid sequence to quantify organism burden (viral load).

Method detailsMay use DNA-specific dyes (eg, SYBR green), hybridization probes (eg, TaqMan), or primer-incorporated probes and report absolute or relative copy numbers.

Clinical useQuantification permits serial assessment of response to treatment (eg, HIV RNA viral load) and is considered separately from non-quantitative indications in this policy.

Multiplex NAAT panels (eg, FilmArray ME, GI, respiratory)

DefinitionMultiplex NAAT panels: assays that detect multiple bacterial, viral, and/or parasitic pathogens in a single run (eg, FilmArray Meningitis/Encephalitis, gastrointestinal pathogen panels, respiratory panels).

Examples citedFilmArray ME panel, XTAG gastrointestinal pathogen panel, various commercial multiplex gastrointestinal and respiratory panels referenced in the literature.

Policy stanceMultiplex NAAT panels for central nervous system and gastrointestinal pathogen panels are specifically noted as not covered / not medically necessary in this policy due to insufficient evidence of improved net health outcome.